Citi has reiterated its’buy’ rating on Apollo Hospitals with a price target of ₹9,600 per share and has added the stock to its pan-Asia focus list as ‘buy’. This is an upside of 34% from its previous close.
Citi has reiterated its’buy’ rating on Apollo Hospitals with a price target of ₹9,600 per share and has added the stock to its pan-Asia focus list as ‘buy’. This is an upside of 34% from its previous close.